Clinical Trial Update: Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) [Phase 2]

View source ↗

Summary

Phase 2 randomized, double-blind trial evaluating BEKINDA (ondansetron 12 mg bimodal release) for diarrhea-predominant irritable bowel syndrome; study completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome with Diarrhea

Drugs mentioned

• BEKINDA (ondansetron)

Snippet

Sponsor: RedHill Biopharma Limited | Conditions: Irritable Bowel Syndrome With Diarrhea | Phase 2 | Status: COMPLETED | Results posted: 2018-07-31